How has the ASCENT trial impacted your management of previously treated metastatic TNBC?  

Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan?

Can data from ASCENT be applied to patients with CNS metastases?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice